Overview

QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

Status:
RECRUITING
Trial end date:
2029-01-02
Target enrollment:
Participant gender:
Summary
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Phase:
PHASE1
Details
Lead Sponsor:
Quanta Therapeutics
Treatments:
Cetuximab